VIDAR-1 trial marks company’s clinical-stage debut

Collaboration brings remote care to cancer patients

EC extends brexpiprazole indication to include adolescents

Immunoglobulin therapy improves mobility in phase 2/3 study

Phase 2a TREE study assesses safety and efficacy of leriglitazone

Company seeks new direction after negative CHMP opinion on KIZFIZO

CervoMed’s therapy demonstrates significant improvement in patients

Oxford Medical Products targets overweight individuals

FSCD therapy meets all endpoints in interim analysis

Scottish Medicines Consortium approves new option for mCRPC patients